Hi, I am Ferdinando Nicoletti, My LiveDNA is 39.5981
 
   
  Home
 
 
 
Prof. Ferdinando Nicoletti
 
Highest Degree: Graduate in Medicine and Surgery from University of Catania, Italy
 
Institute: University of Catania, Italy
 
Area of Interest: Biomedical Sciences
  •   Immunology
  •   Immunopathology
  •   Immunopharmacology
  •   Infectious Diseases
 
URL: http://livedna.org/39.5981
 
My SELECTED Publications
1:   Ablake, M., M. Itoh, T. Kaneko, A. Iimura, Y. Nakamura, P. Meroni and F. Nicoletti, 2002. Short-term prophylaxis with deoxyspergualin prevents testicular autoimmunity in mice. Eur. J. Pharmacol., 450: 209-212.
CrossRef  |  
2:   Abrams, S.L., L.S. Steelman, J.G. Shelton, E.W. Wong and W.H. Chappell et al., 2010. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle, 9: 1781-1791.
3:   Abrams, S.L., L.S. Steelman, J.G. Shelton, W. Chappell and J. Basecke et al., 2010. Enhancing therapeutic efficacy by targeting Non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle, 9: 1839-1846.
4:   Aguilera, E., R. Casamitjana, G. Ercilla, J. Oriola, F. Nicoletti, R. Gomis and I. Conget, 2005. Clinical characteristics, β-cell function, HLA class II and mutations in MODY genes in Non-paediatric subjects with type 1 diabetes without pancreatic autoantibodies. Diabetic Med., 22: 137-143.
CrossRef  |  
5:   Ahlem, C., D. Auci, K. Mangano, C. Reading, J. Frincke, D. Stickney and F. Nicoletti, 2009. HE3286: A novel synthetic steroid as an oral treatment for autoimmune disease. Ann. N. Y. Acad. Sci., 1173: 781-790.
CrossRef  |  
6:   Ahlem, C.N., T.M. Page, D.L. Auci, M.R. Kennedy and K. Mangano et al., 2011. Novel components of the human metabolome: The identification, characterization and Anti-inflammatory activity of two 5-androstene tetrols. Steroids, 76: 145-155.
CrossRef  |  
7:   Al-Abed, Y., D. Dabideen, B. Aljabari, A. Valster and D. Messmer et al., 2005. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem., 280: 36541-36544.
CrossRef  |  
8:   Aljabari, B., A.E. Calogero, A. Perdichizzi, E. Vicari and R. Karaki et al., 2007. Imbalance in seminal fluid MIF indicates male infertility. Mol. Med., 13: 199-202.
CrossRef  |  
9:   Amital, H., Y. Levi, M. Blank, V. Barak and P. Langevitz et al., 1998. Immunomodulation of murine experimental SLE-like disease by interferon-γ. Lupus, 7: 445-454.
Direct Link  |  
10:   Auci, D., F. Nicoletti, K. Mangano, R. Pieters and S. Nierkens et al., 2005. Anti-inflammatory and immune regulatory properties of 5-Androsten-3{beta}, 17{beta}-Diol (HE2100) and synthetic analogue HE3204: Implications for treatment of autoimmune diseases. Ann. N. Y. Acad. Sci., 1051: 730-742.
CrossRef  |  
11:   Barcellini, W., B. Brando, M.O. Borghi, C. Fain, G.P. Rizzardi, F. Nicoletti and P.L. Meroni, 1994. Mutant EL-4 B5 subclone activation system: Cytofluorimetric analysis of B lymphocyte surface markers. J. Clin. Lab. Immunol., 43: 51-67.
12:   Barcellini, W., G.P. Rizzardi, M.O. Borghi, F. Nicoletti, C. Fain, N. Del Papa and P.L. Meroni, 1996. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: Lack of relationship with clinical disease activity. Lupus, 5: 139-145.
PubMed  |  
13:   Barcellini, W., M.O. Borghi, C. Fain, F. Nicoletti, R. Menta, P.L. Meroni and H.U. Schorlemmer, 1993. In vitro effects of deoxyspergualin (DSO) on human peripheral blood mononuclear cells. EOS, 13: 14-15.
14:   Barcellini, W., M.O. Borghi, C. Fain, N. Del Papa, F. Nicoletti and P.L. Meroni, 1992. Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. Clin. Immunol. Immunopathol., 65: 39-44.
CrossRef  |  
15:   Barcellini, W., M.O. Borghi, F. Nicoletti, P. Bonara, C. Fain and P.L. Meroni, 1990. Combination of mutant EL-4 thymoma cells and EBV-infection in B lymphocyte activation a) EBV-infection of EL-4-activated lymphocytes. b) Use of EL-4 cells as feeders for lymphoblastoid cell lines. J. Clin. Lab. Immunol., 33: 21-28.
PubMed  |  
16:   Besong, G., G. Battaglia, M. D'Onofrio, R. di Marco and R.T. Ngomba et al., 2002. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J. Neurosci., 22: 5403-5411.
Direct Link  |  
17:   Boissier, M.C., G. Chiocchia, N. Bessis, J. Hajnal, G. Garotta, F. Nicoletti and C. Fournier, 1995. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur. J. Immunol., 25: 1184-1190.
CrossRef  |  
18:   Borghi, M.O., C. Fain, W. Barcellini, N. Del Papa and L. La Rosa et al., 1994. Ex vivo effect of Pidotimod on peripheral blood mononuclear cell immune functions: Study of an elderly population. Int. J. Immunother., 10: 35-39.
19:   Borghi, M.O., W. Barcellini, C. Fain, F. Nicoletti, N. Del Papa, L. Licciardello and P.L. Meroni, 1992. In vitro effect of MSD53 and its fractions on human mononuclear cells. Int. J. Immunother., 8: 77-84.
20:   Brazillet, M.P., F. Batteux, O. Abeshira-Amar, F. Nicoletti and J. Charreire, 1999. Induction of experimental autoimmune thyroiditis by heat-denaturated porcine thyroglobulin: A Tc1-mediated disease. Eur. J. Immunol., 29: 1342-1352.
21:   Calogero, A.E., F. Nicoletti, M.A. Palumbo, N. Burrello and M. Di Mauro et al., 1998. Macrophage-derived cytokines ih the follicular fluids of women with infertility due to immunological causes. Elevated levels of interleukin-6 and low levels of granulocyte-macrophage colony-stimulating factor. Cytokine, 10: 814-818.
CrossRef  |  
22:   Canducci, F., E.R. Ceresola, D. Saita, Y. Al-Abed, G. Garotta, M. Clementi and F. Nicoletti, 2011. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. Antiviral Res., 91: 292-295.
CrossRef  |  
23:   Cantarella, G., N. Risuglia, G. Lombardo, L. Lempereur, F. Nicoletti, M. Memo and R. Bernardini, 2004. Protective effects of estradiol on TRAIL-induced apoptosis in a human oligodendrocytic cell line: evidence for multiple sites of interactions. Cell Death Differentiation, 11: 503-511.
CrossRef  |  
24:   Celasco, G., L. Moroa, R. Bozzella, P. Ferraboschi and L. Bartorelli et al., 2005. Pharmacological profile of 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity. Arzneimittelforschung, 55: 581-587.
PubMed  |  
25:   Claesson, M.H., F. Nicoletti, S. Stosic-Grujicic, A. Doria and S. Zampieri, 2008. Interactions between infections and Immune-inflammatory cells in type 1 diabetes mellitus and inflammatory bowel diseases: Evidences from animal models. Clin. Exp. Rheumatol., 26: S8-S11.
Direct Link  |  
26:   Cocuzza, C., G. Blandino, R. Mattina, F. Nicoletti and G. Nicoletti, 1997. Antibiotic susceptibility of group A streptococci in 2 Italian cities: Milano and Catania. Microb. Drug. Resist., 3: 379-384.
PubMed  |  
27:   Conget, I., E. Aguilera, S. Pellitero, S. Naf and K. Bendtzen et al., 2005. Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: The FUSIDM trial. Diabetologia, 48: 1464-1468.
CrossRef  |  
28:   Cvetkovic, I., Y. Al-Abed, D. Miljkovic, D. Maksimovic-Ivanic and J. Roth et al., 2005. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology, 146: 2942-2951.
CrossRef  |  
29:   Dati, G., A. Quattrini, L. Bernasconi, M.C. Malaguti and B. Antonsson et al., 2007. Beneficial effects of rh-CLU on disease severity in different animal models of peripheral neuropathies. J. Neuroimmunol., 190: 8-17.
CrossRef  |  
30:   De Carvalho Bittencourt, M., S. Herren, P. Graber, F. Vilbois and C. Pasquali et al., 2005. Extracellular Lysosome-associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the NOD model of type 1 diabetes. Eur. J. Immunol., 35: 1501-1509.
CrossRef  |  
31:   Del Papa, N., P.L. Meroni, W. Barcellini, A. Sinico and A. Radice et al., 1992. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clin. Immunol. Immunopathol., 63: 267-274.
PubMed  |  
32:   Di Marco, R., F. Condorelli, R. Girardello, C. Uslenghi and G. Chisari et al., 1992. Increased rate of survival in Streptococcus pneumoniae-infected rats treated with the new immunomodulator Pidotimod. Scand. J. Infect. Dis., 24: 821-823.
PubMed  |  
33:   Di Marco, R., G. Puglisi, G. Papaccio, A. Nicoletti and F. Patti et al., 2001. Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. Multiple Sclerosis, 7: 101-104.
34:   Di Marco, R., I. Carrabba, V. Cavallaro, P. Zaccone and C. Stazzone et al., 1993. The effect of cefepime on some immune parameters in vitro: Lack of interference with mitogen-induced lymphoproliferation, immunoglobulin synthesis, IFN-gamma and IL-2 secretion and IL-2 receptor expression. J. Chemother., 5: 297-301.
PubMed  |  
35:   Di Marco, R., K. Mangano, C. Quattrocchi, F. Amato, F. Nicoletti and K. Buschard, 2004. Exacerbation of Protracted‐relapsing experimental allergic encephalomyelitis in DA rats by gluten‐free diet. Apmis, 112: 651-655.
CrossRef  |  
36:   Di Marco, R., K. Mangano, C. Quattrocchi, R. Musumeci and A.M. Speciale et al., 2003. Curative effects of sodium fusidate on the development of dinitrobenzene sulfonic acid (DNB)-induced colitis in rats. Clin. Immunol., 109: 266-271.
37:   Di Marco, R., M. Khademi, E. Wallstrom, S. Muhallab, F. Nicoletti and T. Olsson, 1999. Amelioration of experimental allergic neuritis by sodium fusidate (fusidin): Suppression of IFN-gamma and TNF-alpha and enhancement of IL-10. J. Autoimmun., 13: 187-195.
38:   Di Marco, R., M. Khademi, E. Walstrom, E. Iacobeus and A. Salvaggio et al., 2001. Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis. J. Neuroimmunol., 116: 168-177.
CrossRef  |  
39:   Di Marco, R., P. Zaccone, G. Magro, S. Grassoa and M. Lunetta et al., 1996. Synergistic effect of deoxyspergualin (DSP) and cyclosporin A (CsA) in the prevention of spontaneous autoimmune diabetes in BB rats. Clin. Exp. Immunol., 105: 338-343.
CrossRef  |  
40:   Di Marco, R., P. Zaccone, L. Condorelli, C. Leonardi and F. Caccamo et al., 1998. Deoxyspergualin neither counteracts lipopolysaccharide (LPS) or Staphylococcus aureus enterotoxin-B (SEB) induced lethality in mice nor does it modulate the release of tumor necrosis factor-α. Immunol. Lett., 61: 63-66.
CrossRef  |  
41:   Di Paola, R., R. di Marco, E. Mazzon, T. Genovese and K. Bendtzen et al., 2004. Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody. Clin. Immunol., 113: 64-73.
CrossRef  |  
42:   Di Rosa, M., M. Malaguarnera, F. Nicoletti and L. Malaguarnera, 2011. Vitamin D3: A helpful immuno‐modulator. Immunology, 134: 123-139.
CrossRef  |  
43:   Donia, M., B. Cacopardo, M. Libra, G. Scalia, J. A. McCubrey and F. Nicoletti, 2010. New perspectives in HCV Therapy: Entry inhibitors. Recent Patents Anti-Infective Drug Discovery, 5: 181-194.
CrossRef  |  
44:   Donia, M., K. Mangano, A. Amoroso, M.C. Mazzarino and R. Imbesi et al., 2009. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+ CD25+ Foxp3+ regulatory T cells. J. Autoimmunity, 33: 135-140.
CrossRef  |  
45:   Donia, M., K. Mangano, C. Quattrocchi, P. Fagone and S. Signorelli et al., 2010. Specific and Strain‐independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents. Scandinavian J. Immunol., 72: 396-407.
CrossRef  |  
46:   Donia, M., S. Mijatovic, D. Maksimovic-Ivanic, D. Miljkovic and K. Mangano et al., 2009. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. Eur. J. Pharmacol., 615: 228-233.
CrossRef  |  
47:   Doth, M., M. Fricke, F. Nicoletti, G. Garotta, M.L. Van Velthuysen, J.A. Bruijn and E. Gleichman, 1997. Genetic differences in immune reactivity to mercuric chloride (HgCl2): Immunosuppression of H-2d mice is mediated by interferon-gamma (IFN-γ). Clin. Exp. Immunol., 109: 149-156.
CrossRef  |  
48:   Drage, M., P. Zaccone, J.M. Phillips, F. Nicoletti, J. Dawson, J.A. Bradley and A. Cooke, 2002. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice1. Transplantation, 74: 611-619.
49:   Dujmovic, I., K. Mangano, T. Pekmezovic, C. Quattrocchi and S. Mesaros et al., 2009. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J. Neuroimmunol., 207: 101-106.
CrossRef  |  
50:   Fagone, P., K. Mangano, M. Coco, V. Perciavalle, G. Garotta, C.C. Romao and F. Nicoletti, 2012. Therapeutic potential of carbon monoxide in multiple sclerosis. Clin. Exp. Immunol., 167: 179-187.
CrossRef  |  
51:   Galle, P., L. Jensen, C. Andersson, S. Cuzzocrea and R. di Paola et al., 2007. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int. Immunopharmacol., 7: 1704-1713.
CrossRef  |  
52:   Genovese, F., G. Mancuso, M. Cuzzola, V. Cusumano, F. Nicoletti, K. Bendtzen and G. Teti, 1996. Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. Antimicrob. Agents Chemother., 40: 1733-1735.
PubMed  |  
53:   Gorrie, M.J., F.J. Qasim, C.J. Whittle, K.M. Gillespie and C.C. Szeto et al., 2000. Exogenous type 1 cytokines Interferon-gamma and Interleukin-12 suppress the Th2 response induced by mercuric chloride. Clin. Exp. Immunol., 121: 17-22.
54:   Ikematsu, W., F.L. Luan, L. La Rosa, B. Beltrami and F. Nicoletti et al., 1998. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthr. Rheum., 41: 1026-1039.
PubMed  |  
55:   Itoh, M., A. Yano, Q. Xie, K. Iwahashi, Y. Takeuchi, P.L. Meroni and F. Nicoletti, 1998. Essential pathogenic role for endogenous interferon-gamma (IFN-γ) during disease onset phase of murine experimental autoimmune orchitis. I. In vivo studies. Clin. Exp. Immunol., 111: 513-520.
CrossRef  |  
56:   Kaneko, T., M. Itoh, Y. Nakamura, A. Iimura and S. Hayashi et al., 2003. Proinflammatory effects of exogenously administered IL-10 in experimental autoimmune orchitis. Cytokine, 22: 50-53.
CrossRef  |  
57:   La Mantia, I., C. Grillo, T. Mattina, P. Zaccone and M. Xiang et al., 1999. Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome. J. Chemother., 11: 126-130.
58:   Lgssiar, A., M. Hassan, P. Schott-Ohly, N. Friesen, F. Nicoletti, W.L. Trepicchio and H. Gleichmann, 2004. Interleukin-11 inhibits NF-κB and AP-1 activation in islets and prevents diabetes induced with streptozotocin in mice. Exp. Biol. Med., 229: 425-436.
Direct Link  |  
59:   Li, L., M. Itoh, M. Ablake, B. Macri, K. Bendtzen and F. Nicoletti, 2002. Prevention of murine experimental autoimmune orchitis by recombinant human interleukin-6. Clin. Immunol., 102: 135-137.
CrossRef  |  
60:   Libra, M., A. Gloghini, G. Malaponte, P. Gangemi and V. de Re et al., 2008. Association of t (14: 18) translocation with HCV infection in gastrointestinal MALT lymphomas. J. Hepatol., 49: 170-174.
CrossRef  |  
61:   Libra, M., J. Polesel, A.E. Russo, V. de Re and D. Cina et al., 2010. Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia? Int. J. Oncol., 36: 1331-1340.
62:   Libra, M., K. Mangano, M. Anzaldi, C. Quattrocchi and M. Donia et al., 2006. Analysis of interleukin (IL)-1β IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol. Reports, 15: 1305-1308.
Direct Link  |  
63:   Libra, M., M. Indelicato, V. de Re, A.L. Zignego and A. Chiocchetti et al., 2005. Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biol. Ther., 4: 1192-1194.
64:   Ligresti, G., L. Militello, L.S. Steelman, A. Cavallaro and F. Basile et al., 2009. PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches. Cell Cycle, 8: 1352-1358.
65:   Lunetta, M., M. Di Mauro, F. Nicoletti and L. Mughini, 1991. Diabetogenic effect of naloxone in subjects with impaired glucose tolerance. Med. Sci. Res., 19: 737-738.
66:   Lunetta, M., M. Di Mauro, F. Nicoletti and L. Mughini, 1993. Effects of naloxone on immunoreactive insulin and C-peptide response to intravenous glucagon in obese women. Med. Sci. Res., 21: 211-212.
67:   Lunetta, M., M. Di Mauro, G. La Bella, R. Buttiglieri and F. Nicoletti, 1989. The quick-acting effect of regular insulin is preserved in premixed protamine and soluble human insulin preparations. Med. Sci. Res., 17: 897-897.
68:   Lunetta, M., M. Di Mauro, R. Le Moli and F. Nicoletti, 1996. Effect of octreotide on blood glucose and counterregulatory hormones in insulin-dependent diabetic patients: The role of dose and route of administration. Eur. J. Clin. Pharmacol., 51: 139-144.
PubMed  |  
69:   Lunetta, M., M. Di Mauro, R. Le Moli and F. Nicoletti, 1997. Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. Diabetes Res. Clin. Pract., 38: 81-89.
PubMed  |  
70:   Maksimovic-Ivanic, D., S. Mijatovic, L. Harhaji, D. Miljkovic and D. Dabideen et al., 2008. Anticancer properties of the novel nitric Oxide-donating compound (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic Acid-nitric oxide in vitro and in vivo. Mol. Cancer Ther., 7: 510-520.
Direct Link  |  
71:   Maksimovic-Ivanic, D., S. Stosic-Grujicic, F. Nicoletti and S. Mijatovic, 2012. Resistance to TRAIL and how to surmount it. Immunol. Res., 52: 157-168.
CrossRef  |  
72:   Malaguarnera, L., M. di Rosa, A.M. Zambito, N. Dell'Ombra, F. Nicoletti and M. Malaguarnera, 2006. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut, 55: 1313-1320.
CrossRef  |  
73:   Malaguarnera, M., M. di Rosa, F. Nicoletti and L. Malaguarnera, 2009. Molecular mechanisms involved in NAFLD progression. J. Mol. Med., 87: 679-695.
CrossRef  |  PubMed  |  
74:   Mangano, K., A. Nicoletti, F. Patti, M. Donia and L. Malaguarnera et al., 2010. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clin. Exp. Immunol., 159: 159-168.
CrossRef  |  
75:   Mangano, K., G. Dati, C. Quattrocchi, L. Proietti and C. Mazzarino et al., 2008. Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barre syndrome. J. Neuroimmunol., 196: 107-115.
CrossRef  |  
76:   Mangano, K., N. Sardesai, M. D'Alcamo, M. Libra and L. Malaguarnera et al., 2008. In vitro inhibition of enterobacteria-reactive CD4+ CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur. J. Pharmacol., 586: 313-321.
CrossRef  |  
77:   Mangano, K., N.Y. Sardesai, C. Quattrocchi, E. Mazzon and S. Cuzzocrea et al., 2008. Effects of the immunomodulator, VGX‐1027, in endotoxin‐induced uveitis in Lewis rats. Br. J. Pharmacol., 155: 722-730.
CrossRef  |  
78:   Marco, R.D., M. Xiang, P. Zaccone, C. Leonardi, S. Franco, P. Meroni and F. Nicolettl, 1999. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity, 31: 75-83.
Direct Link  |  
79:   McCubrey, J.A., L.S. Steelman, S.L. Abrams, N. Misaghian and W.H. Chappell et al., 2012. Targeting the cancer initiating cell: The ultimate target for cancer therapy. Curr. Pharm. Des., 18: 1784-1795.
Direct Link  |  
80:   McCubrey, J.A., L.S. Steelman, S.L. Abrams, W.H. Chappell and S. Russo et al., 2009. Emerging raf inhibitors. Expert Opin. Emerg. Drugs, 14: 633-648.
CrossRef  |  
81:   McCubrey, J.A., L.S. Steelman, S.L. Abrams, W.H. Chappell and S. Russo et al., 2010. Emerging MEK inhibitors. Expert Opin. Emerg. Drugs, 15: 203-223.
CrossRef  |  
82:   McCubrey, J.A., S.L. Abrams, G. Ligresti, N. Misaghian and E.W.T. Wong et al., 2008. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia, 22: 2080-2090.
CrossRef  |  Direct Link  |  
83:   Meroni, P.L., E. Raschi, M. Camera, C. Testoni and F. Nicoletti et al., 2000. Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome. J. Autoimmun., 15: 237-240.
84:   Mijatovic, S., D. Maksimovic-Ivanic, M. Mojic, G. Malaponte and M. Libra et al., 2008. Novel nitric oxide-donating compound (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic Acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide, 19: 177-183.
CrossRef  |  
85:   Misaghian, N., G. Ligresti, L.S. Steelman, F.E. Bertrand and J. Basecke et al., 2008. Targeting the leukemic stem cell: The Holy Grail of leukemia therapy. Leukemia, 23: 25-42.
CrossRef  |  
86:   Mojic, M., S. Mijatovic, D. Maksimovic-Ivanic, S. Dinic and N. Grdovic et al., 2012. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle, 11: 1174-1182.
87:   Nicoletti, F., A. Creange, D. Orlikowski, F. Bolgert and K. Mangano et al., 2005. Macrophage Migration Inhibitory Factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J. Neuroimmunol., 168: 168-174.
CrossRef  |  
88:   Nicoletti, F., A. Nicoletti, S. Giuffrida, R. Di Marco, P. Meroni, K. Bendtzen and M. Lunetta, 1998. Sodium fusidate in Guillain-Barre syndrome: A case report. J. Neurol. Neurosurg. Psychiatry, 65: 266-268.
CrossRef  |  
89:   Nicoletti, F., B. Beltrami, E. Raschi, R. Di Marco and G. Magro et al., 1997. Protection from concanavalin A (ConA)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. Clin. Exp. Immunol., 110: 479-484.
90:   Nicoletti, F., C. Lamenta, S. Donati, M. Spada and A. Ranazzi et al., 2009. Inhibition of Human Immunodeficiency Virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clin. Exp. Immunol., 155: 28-34.
CrossRef  |  
91:   Nicoletti, F., D. Conrad, A. Wang, R. Pieters and K. Mangano et al., 2009. 16α-Bromoepiandrosterone (HE2000) limits Non-productive inflammation and stimulates immunity in lungs. Clin. Exp. Immunol., 158: 308-316.
CrossRef  |  
92:   Nicoletti, F., F. Patti, A. Nicoletti, M.R. L'Episcopo, R. Di Marco, K. Bendtzen and A. Reggio, 1999. Sodium fusidate in steroid resistant relapses of multiple sclerosis. Multiple Sclerosis, 5: 377-377.
PubMed  |  
93:   Nicoletti, F., F. Patti, C. Cocuzza, P. Zaccone, A. Nicoletti, R. Di Marco and A. Reggio, 1996. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J. Neuroimmunol., 70: 87-90.
CrossRef  |  
94:   Nicoletti, F., F. Patti, R. Di Marco, P. Zaccone, A. Nicoletti, P.L. Meroni and A. Reggio, 1996. Circulating levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine, 8: 395-400.
PubMed  |  
95:   Nicoletti, F., G. Mancuso, F.A. Ciliberti, C. Beninatti, M. Carbone and S. Franco, 1997. Endotoxin-induced lethality in neonatal mice is counteracted by interleukin-10 (IL-10) and exacerbated by anti-IL-10. Clin. Diagn. Lab. Immunol., 4: 607-610.
Direct Link  |  
96:   Nicoletti, F., G. Mancuso, V. Cusumano, R. Di Marco, P. Zaccone, K. Bendtzen and G. Teti, 1997. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. Eur. J. Immunol., 27: 1580-1583.
PubMed  |  
97:   Nicoletti, F., G. Scalia, F. Condorelli, A. Stivala and C. Leonardi et al., 1990. Anti-cytomegalovirus IgM and IgG antibodies, islet cell antibodies and gamma interferon serum levels in newly diagnosed IDDM patients. Int. J. Immunopathol. Pharmacol., 4: 99-106.
98:   Nicoletti, F., G. Scalia, M. Lunetta, F. Condorelli and M. Di Mauro et al., 1990. Correlation between islet cell antibodies and anti-cytomegalovirus IgM and IgG antibodies in healthy first-degree relatives of type 1 (insulin-dependent) diabetic patients. Clin. Immunol. Immunopathol., 55: 139-147.
99:   Nicoletti, F., I. Conget, M. di Mauro, R. di Marco and M. Mazzarino et al., 2002. Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia, 45: 1107-1110.
CrossRef  |  
100:   Nicoletti, F., I. Conget, R. Di Marco, A.M. Speciale, R. Morinigo, K. Bendtzen and R. Gomis, 2001. Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type 1 diabetes. Diabetologia, 44: 309-311.
101:   Nicoletti, F., M. Caruso, M. Di Mauro, S. Stracuzzi and M. Mancuso et al., 1990. CD3+CD25+ cells, CD3+CD4+/CD3+CD8+ ratio, HLA alloantigen association and ICA in type 1 (insulin-dependent) diabetes. Med. Sci. Res., 18: 679-681.
102:   Nicoletti, F., M.O. Borghi, P.L. Meroni, W. Barcellini and C. Fain et al., 1993. Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. Clin. Exp. Immunol., 91: 232-236.
PubMed  |  
103:   Nicoletti, F., M.O. Borghi, W. Barcellini, C. Fain and B. Beltrami et al., 1996. Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. Eur. J. Pharmacol., 311: 213-220.
PubMed  |  
104:   Nicoletti, F., P. Zaccone, G. Magro, W. Barcellini and V. Cavallaro et al., 1994. The effects of thymopentin on the development of SLE-like syndrome in the MRL/lpr-lpr mouse. Scand. J. Immunol., 40: 549-556.
PubMed  |  
105:   Nicoletti, F., P. Zaccone, I. Conget, R. Gomis and C. Moller et al., 1999. Early prophylaxis with recombinant human Interleukin-11 prevents spontaneous diabetes in NOD mice. Diabetes, 48: 2333-2339.
106:   Nicoletti, F., P. Zaccone, M. Xiang, G. Magro and M. Di Mauro et al., 2000. Essential pathogenetic role for interferon (IFN-)γ in concanavalin a-induced T cell-dependent hepatitis: Exacerbation by exogenous IFN-γ and prevention by IFN-γ RECEPTOR-immunoglobulin fusion protein. Cytokine, 12: 315-323.
CrossRef  |  
107:   Nicoletti, F., P. Zaccone, R. Di Marco, G. Magro and S. Grasso et al., 1995. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology, 85: 645-650.
PubMed  |  
108:   Nicoletti, F., P. Zaccone, R. Di Marco, G. Magro and S. Grasso et al., 1998. Paradoxical antidiabetogenic effect of gamma-interferon in DP-BB rats. Diabetes, 47: 32-38.
PubMed  |  
109:   Nicoletti, F., P. Zaccone, R. Di Marco, M. Di Mauro and G. Magro et al., 1996. The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology, 137: 5567-5575.
PubMed  |  
110:   Nicoletti, F., P. Zaccone, R. Di Marco, M. Lunetta and G. Magro et al., 1997. Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody. Endocrinology, 138: 281-288.
PubMed  |  
111:   Nicoletti, F., P.L. Meroni and K. Bendtzen, 1996. Fusidic acid and insulin-dependent diabetes mellitus. Autoimmunity, 24: 187-197.
PubMed  |  
112:   Nicoletti, F., P.L. Meroni, M. Lunetta, R. Vigo and T. Palermo et al., 1991. Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. Lancet, 337: 1292-1292.
PubMed  |  
113:   Nicoletti, F., P.L. Meroni, R. Di Marco, S. Grasso and W. Barcellini et al., 1992. The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. Scand. J. Immunol., 36: 415-420.
CrossRef  |  
114:   Nicoletti, F., P.L. Meroni, R. Di Marco, W. Barcellini and M.O. Borghi et al., 1992. In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. Immunopharmacology, 24: 11-16.
PubMed  |  
115:   Nicoletti, F., P.L. Meroni, S. Landolfo, M. Gariglio and S. Guzzardi et al., 1990. Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-γ. Lancet, 336: 319-319.
CrossRef  |  
116:   Nicoletti, F., P.L. Meroni, W. Barcellini, P.O. Steinsvag and M. Di Mauro et al., 1990. Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients. Immunol. Lett., 23: 211-216.
CrossRef  |  
117:   Nicoletti, F., P.L. Meroni, W. Barcellini, S. Grasso and M.O. Borghi et al., 1991. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. Int. J. Immunopharmacol., 13: 1027-1030.
PubMed  |  
118:   Nicoletti, F., R. Di Marco, F. Patti, A. Nicoletti and C. Leonardi et al., 2000. The antiinflammatory cytokine interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells. Autoimmunity, 32: 265-270.
PubMed  |  
119:   Nicoletti, F., R. Di Marco, F. Patti, E. Reggio and A. Nicoletti et al., 1998. Blood levels of transforming growth factor‐beta 1 (TGF‐β1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon‐beta 1b (IFN‐β1b). Clin. Exp. Immunol., 113: 96-99.
CrossRef  |  
120:   Nicoletti, F., R. Di Marco, F. Patti, P. Zaccone and M.R. L'Episcopo et al., 2000. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine, 12: 682-687.
PubMed  |  
121:   Nicoletti, F., R. Di Marco, I. Conget, R. Gomis and C. Edwards et al., 2000. Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin. J. Autoimmun., 15: 395-405.
CrossRef  |  
122:   Nicoletti, F., R. Di Marco, K. Mangano, F. Patti and E. Reggio et al., 2001. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology, 57: 342-344.
CrossRef  |  
123:   Nicoletti, F., R. Di Marco, P. Sacerdote, P. Meroni and K. Mangano et al., 2001. Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14. Antimicrob. Agents Chemother., 45: 1591-1594.
CrossRef  |  Direct Link  |  
124:   Nicoletti, F., R. Di Marco, P. Zaccone, A. Salvaggio, G. Magro, K. Bendtzen and P.L. Meroni, 2000. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. Hepatology, 32: 728-733.
PubMed  |  
125:   Nicoletti, F., R. Di Marco, P. Zaccone, G. Magro, M. Di Mauro, S. Grasso and P.L. Meroni, 1999. Endogenous interleukin-12 only plays a key pathogenetic role in NOD mouse diabetes during the very early stage of the disease. Immunology, 97: 367-370.
CrossRef  |  
126:   Nicoletti, F., R. Di Marco, P. Zaccone, M. Xiang and G. Magro et al., 2000. Dichotomic effects of IFN-γ on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice. Eur. J. Immunol., 30: 438-447.
CrossRef  |  
127:   Nicoletti, F., R. Di Marco, S. Morrone, P. Zaccone and D. Lembo et al., 1994. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. Immunology, 81: 317-321.
PubMed  |  
128:   Nicoletti, F., R. Di Marco, W. Barcellini, G. Magro and H.U. Schorlemmer et al., 1994. Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur. J. Immunol., 24: 1843-1847.
CrossRef  |  
129:   Nicoletti, F., R. Di Marco, W. Barcellini, M.O. Borghi, M. Lunetta, L. Mughini and P.L. Meroni, 1994. Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin. Scand. J. Immunol., 39: 333-336.
PubMed  |  
130:   Nicoletti, F., R.D. Marco, G. Papaccio, I. Conget and R. Gomis et al., 2003. Essential pathogenic role of endogenous IL‐18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant IL‐18‐binding protein: Fc construct. Eur. J. Immunol., 33: 2278-2286.
CrossRef  |  
131:   Nicoletti, F., U. Consoli, D. Calogero, A.M. Speciale and R. Di Marco et al., 1991. Enhanced percentage of Leu M3+DR+ and Leu M3+CD25+ cells in newly diagnosed IDDM patients. Autoimmunity, 9: 255-259.
PubMed  |  
132:   Panerai, A.E., F. Nicoletti, P. Sacerdote, L. Arvidsson and I. Conget et al., 2001. MFP14, a multifunctional emerging protein with immunomodulatory properties, prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetologia, 44: 839-847.
CrossRef  |  
133:   Panerai, A.E., P. Sacerdote, M. Bianchi, F. Nicoletti and B. Manfredi et al., 1999. Chronic administration of UK‐114, a multifunctional emerging protein, modulates the Th1/Th2 cytokine pattern and experimental autoimmune diseases. Ann. N. Y. Acad. Sci., 876: 229-235.
CrossRef  |  
134:   Papaccio, G., A. Graziano, S. Valiante, R. D'Aquino, S. Travali and F. Nicoletti, 2005. Interleukin (IL)‐1β toxicity to islet β cells: Efaroxan exerts a complete protection. J. Cell. Physiol., 203: 94-102.
CrossRef  |  
135:   Papaccio, G., F. Nicoletti, F.A. Pisanti and K. Bendtzen, 2000. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology, 141: 1500-1505.
PubMed  |  
136:   Papaccio, G., F. Nicoletti, F.A. Pisanti, M. Galdieri and K. Bendtzen, 2002. An imidazoline compound completely counteracts interleukin-1 [beta] toxic effects to rat pancreatic islet [beta] cells. Mol. Med., 8: 536-545.
Direct Link  |  
137:   Patti, F., M.L. Cataldi, F. Nicoletti, E. Reggio, A. Nicoletti and A. Reggio, 2001. Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 71: 404-407.
CrossRef  |  
138:   Perdichizzi, A., F. Nicoletti, S. la Vignera, N. Barone, R. D'Agata, E. Vicari and A.E. Calogero, 2007. Effects of tumour necrosis factor-α on human sperm motility and apoptosis. J. Clin. Immunol., 27: 152-162.
CrossRef  |  
139:   Piona, A., L. La Rosa, A. Tincani, D. Faden and G. Magro et al., 1995. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. Scand. J. Immunol., 41: 427-432.
PubMed  |  
140:   Recasens, M., E. Aguilera, R. Morinigo, R. Casamitjana, F. Nicoletti, R. Gomis and I. Conget, 2003. Insulin lipro is a s effective as regular insulin in optimising metabolic control and preserving β-cell function at onset of type 1 diabetes mellitus. Diabetes Res. Clin. Pract., 3: 153-159.
CrossRef  |  
141:   Sokolosky, M.L., K.M. Stadelman, W.H. Chappell, S.L. Abrams and A.M. Martelli et al., 2011. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget, 2: 538-550.
Direct Link  |  
142:   Steelman, L.S., K.M. Stadelman, W.H. Chappell, S. Horn and J. Basecke et al., 2008. Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets, 12: 1139-1165.
CrossRef  |  
143:   Stojanovic, I., S. Cuzzocrea, K. Mangano, E. Mazzon and D. Miljkovic et al., 2007. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin. Immunol., 123: 311-323.
CrossRef  |  
144:   Stosic-Grujicic, S., I. Cvetkovic, K. Mangano, M. Fresta and D. Maksimovic-Ivanic et al., 2007. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J. Pharmacol. Exp. Ther., 320: 1038-1049.
PubMed  |  
145:   Stosic-Grujicic, S., I. Stojanovic, D. Maksimovic-Ivanic, M. Momcilovic and D. Popadic et al., 2008. Macrophage Migration Inhibitory Factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J. Cell. Physiol., 215: 665-675.
CrossRef  |  
146:   Tang, H., K. Mignon-Godefroy, P.L. Meroni, G. Garotta, J. Charreire and F. Nicoletti, 1993. The effects of a monoclonal antibody to interferon-gamma on experimental autoimmune thyroiditis (EAT): Prevention of disease and decrease of EAT-specific T cells. Eur. J. Immunol., 23: 275-278.
PubMed  |  
147:   Xiang, M., P. Zaccone, R. Di Marco, G. Magro and M. Di Mauro et al., 1999. Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice. Eur. J. Pharmacol., 367: 399-404.
CrossRef  |  
148:   Xiang, M., P. Zaccone, R.D. Marco, R. Harris and G. Magro et al., 1999. Failure of exogenously administered interferon-γ or blockage of endogenous interleukin-4 with specific inhibitors to augment the incidence of autoimmune diabetes in male NOD mice. Autoimmunity, 30: 71-80.
Direct Link  |  
149:   Zaccone, P., J. Phillips, I. Conget, A. Cooke and F. Nicoletti, 2005. IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse. Clin. Immunol., 115: 74-79.
CrossRef  |  
150:   Zaccone, P., J. Phillips, I. Conget, R. Gomis and K. Haskins et al., 1999. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes, 48: 1522-1528.
Direct Link  |  
151:   Zaccone, P., P. Hutchings, F. Nicoletti, G. Penna, L. Adorini and A. Cooke, 1999. The involvement of IL‐12 in murine experimentally induced autoimmune thyroid disease. Eur. J. Immunol., 29: 1933-1942.
CrossRef  |  
152:   Zaccone, P., Z. Fehervari, L. Blanchard, F. Nicoletti, C.K. Edwards III and A. Cooke, 2002. Autoimmune thyroid disease induced by thyroglobulin and lipopolysaccharide is inhibited by soluble TNF receptor type I. Eur. J. Immunol., 32: 1021-1028.
CrossRef  |